Latest News - Eli Lilly
Top Corporates Hub
Eli Lilly
Janus Henderson Forty Fund’s Updates on Eli Lilly and Company (LLY)
27.03.2026 15:56
Janus Henderson Investors, an investment management company, released its “Forty Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. shares increased following positive news about corporate earnings. Economic growth has remained relatively stable despite challenges such as a government shutdown, policy headwinds, and slower-than-expected employment growth. Excitement around artificial […]
WVE Posts Interim Data From Phase I Study on WVE-007, Stock Tanks
27.03.2026 15:24
Wave Life Sciences stock plunges after interim phase I data for WVE-007 showed modest fat reduction at higher dose, despite some sustained benefits.
Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is the Better Buy?
27.03.2026 15:20
It's not much of a contest right now.
Anti-Cancer MAbS Market Report 2026-2030 Featuring Strategic Analysis of Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, Roche, GlaxoSmithKline and Other Key Players
27.03.2026 14:49
Opportunities in the anti-cancer mAbs market include growth in personalized cancer medicine, expansion of biosimilar mAbs, and increased oncology spending Anti-Cancer MAbS Market Anti-Cancer MAbS Market Dublin, March 27, 2026 (GLOBE NEWSWIRE) -- The "Anti-Cancer MAbS Market Report 2026" has been added to ResearchAndMarkets.com's offering. The anti-cancer monoclonal antibodies (mAbs) market has recently experienced robust growth, expanding from $71.25 billion in 2025 to $78.12 billion in 2026, re
VKTX Finishes Enrollment in Second Late-Stage Study on Obesity Drug
27.03.2026 14:00
Viking Therapeutics climbs after it completes enrollment in the second phase III obesity study for VK2735 and advances its bid in a fast-growing, competitive weight-loss market.
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
27.03.2026 13:00
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
27.03.2026 13:00
New long-term data show Eli Lilly and Company's (NYSE: LLY) EBGLYSS (lebrikizumab-lbkz) delivered durable skin clearance and relief from persistent itch for up to four years for patients with moderate-to-severe atopic dermatitis (eczema) in an open-label extension study offering once-monthly maintenance injection. Interim findings from the first year of the ADlong Phase 3b study will be presented at the American Academy of Dermatology (AAD) Annual Meeting, taking place March 27-31 in Denver.1
Why Pfizer Remains A Strong Buy In 2026
27.03.2026 10:46
Pfizer started 2026 on a high note despite ongoing skepticism from retail investors. Click here to find out why PFE stock is a Strong Buy.
Eli Lilly Says New Long-Term Data From EBGLYSS Delivers Durable Skin Clearance And Relief From Persistent Itch For Up To Four Years For Patients With Eczema In Open-Label Extension Study Offering Once-Monthly Maintenance Injection
27.03.2026 09:03
In the ADlong Phase 3b study, nearly all EBGLYSS-treated patients achieved meaningful skin improvement (EASI-75) for up to four years75% of patients achieved a high bar of near-complete skin clearance (EASI-90) and 78%
Novo Nordisk: A Comeback Story In The World's Fastest-Growing Drug Market
27.03.2026 06:48
Novo Nordisk is positioned as a durable No. 2 in the obesity drug market, not a loser to Eli Lilly. Click here to read an analysis of NVO stock now.
MeiraGTx Highlights Late-Stage Gene Therapy Pipeline at RBC Ophthalmology Conference
26.03.2026 10:15
MeiraGTx (NASDAQ:MGTX) is advancing a portfolio of gene therapy programs across ophthalmology and other large disease areas, President and CEO Alexandria “Zandy” Forbes said during an RBC Capital Markets ophthalmology conference discussion with biotech analyst Lisa Walter. Forbes described the comp
Faron Pharmaceuticals Ltd: Faron Appoints New CTO to Strengthen Late-Stage Development Activities
26.03.2026 07:20
TURKU, FI / ACCESS Newswire / March 26, 2026 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company, announces the appointment of Mr. Heikki Jouttijärvi as the Company's Chief Technical Officer (CTO). ...
Growing Optimism About ProQR Therapeutics (PRQR)’s RNA Editing Platform and Future Clinical Catalysts
25.03.2026 19:29
ProQR Therapeutics N.V. (NASDAQ:PRQR) earns a spot in our list of the top 10 stocks under $5 that could triple. As of March 19, 2026, analysts remain confident in ProQR Therapeutics N.V. (NASDAQ:PRQR), with 100% maintaining “Buy” ratings. The consensus price target of $9.44 implies a 448.56% upside, reflecting growing optimism about the company’s RNA […]
Is Eli Lilly (LLY) The Best Healthcare Stock to Buy According to Jim Cramer?
25.03.2026 14:36
We just covered the Jim Cramer Stock Portfolio: Top 10 Stock Picks. Eli Lilly and Company (NYSE:LLY) ranks #9 (see the Jim Cramer’s top 5 stock picks in 2026 here). Jim Cramer has long been a believer in Eli Lilly and Company (NYSE:LLY). In November, he said on CNBC that the company is likely to […]
Eli Lilly (LLY) Gained From Growth in its GLP-1 Franchises Drugs
25.03.2026 14:21
RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark Large Growth Fund” Q4 2025 investor letter. A copy of the letter can be downloaded here. The US stock market delivered modest gains in the quarter with the S&P 500 index (“S&P”) and the Russell 1000 Growth […]
LLY or ABBV: Which Drugmaker is Likely to Offer Better Upside in 2026?
25.03.2026 12:55
LLY's obesity drugs fuel explosive growth, while ABBV depends on Skyrizi and Rinvoq. Let's see which drugmaker has the stronger 2026 outlook.
Is Novo Nordisk's Experimental Obesity Drug Outperforming Semaglutide?
25.03.2026 09:36
Novo Nordisk says UBT251 cuts blood sugar levels and weight more than semaglutide in a Chinese phase 2 trial.
Semafor Reported Senators Reach Deal On Capping Insulin Costs At $35
25.03.2026 06:23
https://www.semafor.com/article/03/24/2026/senators-reach-deal-on-capping-insulin-costs-at-35
Novo Nordisk Vs. Eli Lilly: Cheap Vs. Expensive, But No Clear Opportunity
25.03.2026 05:21
Novo Nordisk and Eli Lilly are both strong GLP-1 players, but current market narratives do not support fundamentals. See why I rate NVO and LLY stocks Hold.
Morgan Stanley Reiterates Overweight on Eli Lilly (LLY), Cites Growth Potential of New Platform
24.03.2026 11:27
Eli Lilly & Company (NYSE:LLY) ranks among the best high profit margin stocks to buy. Following the reveal of an innovative employer access platform for obesity therapies, Morgan Stanley reiterated its Overweight rating and $1,313 price target for Eli Lilly & Company (NYSE:LLY) on March 5. Eli Lilly recently established its Employer Connect platform in […]